Moderna (XSWX:MRNA) GF Score: 62/100 (As of Jul. 02, 2026) — Near Median


XSWX:MRNA Moderna Inc XSWX:MRNA
62 GF Score
Price CHF57.81
GF Value CHF18.28
! 7 Warning Signs
View Full Analysis

What is Moderna GF Score?

Moderna XSWX:MRNA 62 GF Score is 62 as of Jul. 02, 2026, which is 2% above its 10-year median of 61.00. GuruFocus rates XSWX:MRNA with a GF Score™ of 62/100 and a GF Value™ of CHF18.28. The stock has 7 warning signs investors should review.

Moderna has the GF Score of 62, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 3/10
3. Growth Rank : 7/10
4. GF Value Rank : 1/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Moderna might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Moderna  (XSWX:MRNA) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Moderna GF Score Related Terms

XSWX:MRNA vs RPRX, ROIV, ONC: GF Score Comparison

For the Biotechnology subindustry, Moderna's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's GF Score distribution charts can be found below:

* The bar in red indicates where Moderna's GF Score falls into.


XSWX:MRNA
62GF Score
Moderna Inc XSWX:MRNA
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 62 mean?
Moderna (XSWX:MRNA) has a GF Score of 62 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Moderna and its competitors. This is near median its historical median of 61.00. Over the past decade, Moderna's GF Score has ranged from 54.00 to 66.00.
Is Moderna's GF Score too high?
Moderna's current GF Score of 62 is near median its 10-year median of 61.00. Over the past 10 years, this metric has ranged from a low of 54.00 to a high of 66.00. Overall, Moderna has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's GF Score compare to RPRX and ROIV?
Moderna's GF Score of 62 can be compared against companies in the Biotechnology industry. Historically, Moderna's own GF Score has ranged from 54.00 to 66.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Moderna and its competitors. Moderna's current GF Score is 62, which is near median its own 10-year median of 61.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (XSWX:MRNA) has a current GF Score of 62. The stock's GF Value™ is CHF18.28, compared to a current price of CHF57.81 — trading 216.2% above its estimated fair value. The current GF Score is 62, which is near median its 10-year median of 61.00. Moderna's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Moderna (XSWX:MRNA), the current GF Score is 62 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (XSWX:MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of CHF57.81 is trading 216.2% above its estimated GF Value™ of CHF18.28.

Key valuation signals for XSWX:MRNA:

  • GF Score: 62 (near median its 10-year median of 61.00)
  • GF Value™: CHF18.28 vs. price of CHF57.81 (216.2% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the XSWX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
62GF Score

Get the complete analysis for XSWX:MRNA

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF57.81
Price
CHF18.28
GF Value